Alder Biopharmaceuticals Appoints Clay B. Siegall, Ph.D., to Board.BOTHELL, Wash. -- Alder alder (ôl`dər), name for deciduous trees and shrubs of the genus Alnus of the family Betulaceae (birch family), widely distributed, especially in mountainous and moist areas of the north temperate zone and in the Andes. Biopharmaceuticals Inc., an early-stage antibody therapeutics company, today announced the appointment of Clay B. Siegall, Ph.D., to its board of directors. "Dr. Siegall is an industry leader and a pioneer in the research and development of targeted cancer therapies," said Dr. Randall Schatzman, Alder CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and co-founder. "He brings deep experience in the field of antibody therapeutics, and his entrepreneurial work with Seattle Genetics has given him extensive, firsthand knowledge of how to build a successful biotechnology company. We're excited to add his insights and knowledge to our board." Dr. Siegall brings nearly 20 years of experience in cancer research and therapeutic drug development to Alder. His expertise is coupled with the operational, financial and practical experience of running Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ), which he co-founded in 1998 and currently leads as President, Chief Executive Officer, and a member of the board. Under his leadership, Seattle Genetics has developed a diverse portfolio of clinical and preclinical product candidates targeting a variety of cancer and autoimmune indications. Seattle Genetics is also a recognized leader in antibody technologies, notably its antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ) platform. Dr. Siegall has also guided Seattle Genetics' capital-raising activities, securing more than $230 million through public and private financings, including the company's initial public offering in 2001. In addition, the company has entered into multiple strategic collaborations, including agreements with Genentech, MedImmune, CuraGen, Bayer and PDL See page description language. 1. PDL - Page Description Language. 2. PDL - Program Design Language. 3. PDL - Push Down List. 4. PDL - Dave Lebling, one of the co-authors of Zork. BioPharma that have generated over $50 million since 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. Dr. Siegall received a Ph.D. in Genetics from George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. and a B.S. in Zoology zoology, branch of biology concerned with the study of animal life. From earliest times animals have been vitally important to man; cave art demonstrates the practical and mystical significance animals held for prehistoric man. from the University of Maryland University of Maryland can refer to:
Commenting on his appointment, Dr. Siegall said, "I'm excited to join Alder at this important juncture. Alder's technologies have strong potential to impact the field of antibody therapeutics. I look forward to working with Alder's talented team as they begin to capitalize on encouraging early results." Alder's unique contribution to the field of antibody therapeutics involves a platform of proprietary antibody technologies that industrializes the approach to developing, selecting and manufacturing antibody therapeutics. Alder's technologies have the potential to dramatically accelerate progress to the clinic while at the same time providing an inexpensive and rapid route through product manufacturing. For more information or to set up a non-disclosure agreement to learn about Alder's proprietary technologies in more detail, please contact Mark Litton, Chief Business Officer, at 425-205-2920 or litton@alderbio.com. About Alder Founded in January 2004, Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas, with extensions into certain forms of cancer. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. The company recently completed a Series A financing led by Sevin Rosen Funds Sevin Rosen Funds (SRF) is a venture capital firm that was established in 1981 by L.J. Sevin and Ben Rosen. SRF was involved in the financing of ArQule, CIENA, Citrix, Cypress Semiconductor, Electronic Arts, Lotus Development Corporation, Silicon Graphics, and Vitesse. and other investors in August 2005. Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. For more information, visit www.alderbio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion